An Open Label Study of the Safety During Treatment With Tocilizumab (TCZ), in Combination With Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Rheumatoid Arthritis.

Trial Profile

An Open Label Study of the Safety During Treatment With Tocilizumab (TCZ), in Combination With Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2014

At a glance

  • Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 15 Aug 2012 Actual patient number changed from 31 to 61 as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Actual initiation date changed from Sep 2010 to Oct 2010, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top